The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

  • End date
    Oct 25, 2028
  • participants needed
  • sponsor
    Yonsei University
Updated on 25 January 2021


The purpose of this study is to investigate the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) in atrial fibrillation patients with intermediate stroke risk (CHA2DS2-VASc score 1 for male, 2 for female).

  1. Major safety results include major bleeding and clinically relevant non-major bleeding.
  2. Major efficacy results include strokes, systemic embolism and mortality. C. Other results include myocardial infarction, pulmonary embolism, transient ischemic attack, hospitalization, drug compliance, quality of life questionnaire (AFEQT), cognitive function (KDSQ), aging questionnaire(K-Frail) and hand grip strength.

Condition Atrial Fibrillation Patients With Intermediate Stroke Risk
Treatment Anticoagulation group(Apixaban group)
Clinical Study IdentifierNCT04437654
SponsorYonsei University
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Age: 19~80 years old
CHA2DS2-VASc score 1 for male or 2 for female among nonvalvular atrial fibrillation patients
Patients who agree to register for this study
Patients who can be observed for the progress after treatment

Exclusion Criteria

Severe liver or kidney dysfunction
Thyroid dysfunction
Pregnant or breastfeeding women
Malignant tumors that have not been completely cured
Severe structural heart disease
Predicted survival is less than 12 months
Patients who do not understand the content of the study or disagree with it
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note